List view / Grid view

Modra Pharmaceuticals

 

article

Solving the taxing problems of taxanes?

4 November 2022 | By

Could the new wave of taxane chemotherapies succeed where traditional chemotherapies have failed? Colin Freund, Chief Executive Officer of Modra Pharmaceuticals, reveals the benefits of this emerging generation of anticancer treatment.

article

Drug Formulation In-Depth Focus 2022

27 October 2022 | By

Articles in this drug formulation In-Depth Focus explore the design of formulations using cyclodextrins, plus the development of orally-delivered taxane chemotherapies.